Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.

"Disclosures Dr Zeller reports that he is a member of the advisory board of Medtronic (Covidien), Spectranetics, Veryan, Boston Scientific, W.L. Gore, and TriReme. Dr Rocha-Singh reports that he is a consultant for Medtronic (Covidien), Alucent, and Zimmer-Biomet and a member of the Board of Vascular Interventional Advances Physicians—a 501c3 not-for-profit education and research organization. Dr Jaff reports that he is a noncompensated advisor for Medtronic (Covidien) and a compensated member of the Board of Vascular Interventional Advances Physicians. Dr Blessing reports that he receives speaker’s honoraria for Medtronic. Dr Scheinert reports that he is on the advisory board and acts for a consultant for Abbott, Biotronik, Boston Scientific, Cook Medical, Cordis, CR Bard, Gardia Medical, Medtronic (Covidien), TriReme Medical, Trivascular, and Upstream Peripheral Technologies. Dr Langhoff reports that he receives speaker’s honoraria for Medtronic and that he is consultant for Biotronik, B. Braun Melsungen, Boston Scientific, dp-medsystems, Contego Medical, Terumo, and Abbott Vascular. Dr Tepe receives Medtronic study support and is a member of the advisory board. The other authors report no conflicts."

"Sources of Funding The study was an investigator-initiated study with industry funding from Covidien (now Medtronic PLC, Santa Rosa, CA). Study cohort size was limited by funding."

"Clinical Trial Registration— http://www.clinicaltrials.gov. Unique Identifier: NCT01366482."